Why uniQure N.V.’s (QURE) Stock Is Up 7.18%
As of Wednesday, September 30, uniQure N.V.’s QURE share price has surged by 7.18%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Commentary & Analysis
Why uniQure N.V.’s (QURE) Stock Is Down 38.19%
As of Tuesday, September 29, uniQure N.V.’s QURE share price has dipped by 38.19%, which has investors questioning if this is right time to buy.Jenna Brashear
Why uniQure N.V.’s (QURE) Stock Is Down 36.88%
As of Tuesday, September 29, uniQure N.V.’s QURE share price has dipped by 36.88%, which has investors questioning if this is right time to buy.Jenna Brashear
Why uniQure N.V.’s (QURE) Stock Is Down 6.31%
As of Thursday, September 24, uniQure N.V.’s QURE share price has dipped by 6.31%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why uniQure N.V.’s (QURE) Stock Is Down 10.94%
As of Thursday, September 24, uniQure N.V.’s QURE share price has dipped by 10.94%, which has investors questioning if this is right time to buy.Tudor Pop
Financial Summary
| Share Statistics | QURE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,627.3 | $250.1 | 52% |
|
| Shares Out (Mil) | 66.2 | 54.0 | 54% |
|
| Institutional Ownership | 98.0% | 93.1% | 76% |
|
| Float (Mil) | 57.5 | 41.4 | 50% |
|
| Beta | 0.94 | 0.95 | 56% |
|
| Avg Daily Volume (000s) | 5,277 | 661 | 92% |
|
| Price Change (52-week) |
(57.3%) | 49.5% | 15% |
|
| Growth | QURE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (15.6%) | 12.5% | 3% |
|
| Net Income (5yr) | (9.7%) | (10.1%) | 30% |
|
| EPS (5yr) | (4.2%) | 15.8% | 26 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 14.5% | (15.7%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.929) | ($3.879) | ($3.031) | |
| Month Ago EPS | ($0.923) | ($3.858) | ($2.911) | |
| # Rev Up | 2 | 0 | 1 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.913) | ($3.554) | ($2.842) | |
| Year/Year Chg | (24.1%) | 12.1% | (81.0%) | |
| Financials | QURE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $19 | $37 | 12% |
|
| Net Income (TTM) (Mil) | ($252) | ($44) | 6% |
|
| EPS (TTM) | ($4.036) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($161) | ($33) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $159 | $2 | 82% |
|
| Long-Term Debt (Q1) (Mil) | $549 | $4 | 60% |
|
| Enterprise Value (Q1) (Mil) | $2,794 | $175 | 53% |
|
| Valuation | QURE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.02 | 2.36 | 80% |
|
| P/E | na | 18.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | QURE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (614.3%) | 67.3% | 0% |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (32.1%) | (47.6%) | 16% |
|
| ROE | (157.6%) | (54.9%) | 6% |
|
| Liabilities to Assets | 67.1% | 29.3% | 63% |
|
| F-Score | 4 | 3 | 33% |
|
uniQure N.V. did not pass any screens on 10/2/2026.
